Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Procedure: Brain electrical activity monitorDiagnostic Test: Biochemical determinationsDiagnostic Test: Pharmacokinetic Study of Sublingually Administered Psychoactive SubstanceDiagnostic Test: Acute Subjective Ratings of Psychedelic EffectsDiagnostic Test: vital signsDiagnostic Test: Cognitive AssessmentsDiagnostic Test: Psychiatric Assessments
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Biomind Labs Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06816667
- Locations
- 🇦🇷
Hospital Descentralizado Dr. Marcial V. Quiroga., San Juan, Rivadavia, Argentina
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
Phase 1
Completed
- Conditions
- Mild Cognitive ImpairmentAnxiety StateDepression Anxiety Disorder
- Interventions
- Drug: Sublingual administrationProcedure: ElectroencephalographyDiagnostic Test: Biochemical mesurementsDiagnostic Test: Acute Subjective Ratings of Psychedelic EffectsDiagnostic Test: Vital signsDiagnostic Test: Cognitive AssessmentsDiagnostic Test: Psychiatric Assessments
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Biomind Labs Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06812221
- Locations
- 🇦🇷
Hospital Descentralizado Dr. Marcial V. Quiroga., San Juan, Rivadavia, Argentina
Clinical Study of DMT in Healthy Adults
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Biomind Labs Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05573568
- Locations
- 🇧🇷
Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil
© Copyright 2025. All Rights Reserved by MedPath